The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.
about
Adult vaccinationInfluenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based reviewPneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspringEvolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-upRationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or olderMultiplex PCR for identification of seven Streptococcus pneumoniae serotypes targeted by a 7-valent conjugate vaccine.Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in miceClinical efficacy of anti-pneumococcal vaccination in patients with COPD.Efficacy of pneumococcal vaccination in adults: a meta-analysis.Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study.Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP)Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus.Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.Pneumonia immunization in older adults: review of vaccine effectiveness and strategiesRecommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results.General practitioners' experiences, attitudes, and opinions regarding the pneumococcal vaccination for adults: a qualitative study.Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly.Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.Biology of immune responses to vaccines in elderly persons.The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study.Carbohydrate-based vaccines: challenges and opportunities.Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Aging of the immune system: Focus on inflammation and vaccination.Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009.Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005.Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies.Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
P2860
Q26824961-CD196E9D-53C7-41A9-9122-6262E805D250Q27007003-D27D642C-CC57-49EC-BD1A-DB6993ABD14FQ28070059-5D7CB8FB-2579-4F05-90CE-BFBC9B00BCFAQ28743311-95F7F6F7-6EEA-4C35-AFE5-6954682210D0Q33257893-EF1F3EA7-8823-42C2-8003-90100F6CFEFFQ33525198-5DF6952F-BC00-4B17-8B45-2E1644F1F306Q33542866-7038281E-7930-493A-9C56-1225112BCA13Q33885199-E9BD0AC9-98DF-4A1F-8B0F-14507AB74845Q33963100-655000FA-8233-471C-B49E-65F4EB14E9D5Q34444975-3FB6F51D-5487-473B-B2DF-6D08BBA9D553Q34561776-A3935672-940A-402B-9388-AE3BE5A3D46CQ34657877-D53EE114-1883-4CB5-84A4-336DDF07E861Q35091736-37EB328C-7FDD-4BAF-84DA-3E56A7462F51Q35616635-789F4421-DA5A-4408-AD49-E8D0C1F97EDDQ35914703-C81FE1CF-2D7B-4F37-9048-E9DA7AE5341CQ36128243-F30D34BA-C80F-44F8-A85A-4493551FC8B6Q36191655-40826CDB-4CAA-4017-BC97-E26156081257Q36343776-8D9D7812-2531-4DAC-8718-0B0327473A4AQ36393396-665DFD70-8CA0-49D2-87F3-CE2ACA25DAD8Q36406774-7E835F8C-084E-4325-9D4E-18AF930541ADQ36406778-36A55028-7611-4787-8C40-972211E7AA7CQ36429665-A02966F8-0580-49C2-B6AD-469C18639333Q36864896-0C28DCB5-B75B-4685-85B0-97A79C9FD1E1Q37077655-AD0977C4-0A4E-49D4-B431-7C2A2C7C2DA4Q37078104-996C26EA-B7EA-4ECF-B591-08413CAFD26BQ37145037-E6BC428B-7A1A-4981-97FD-2B2CC109773CQ37150299-74A75896-A3D3-4ABE-A204-8D7463203028Q37306236-A9B5F560-0E9F-44FB-9A45-79924B920ED7Q37810597-04E0AC86-C627-4EDD-8027-DCD90AC3B8E0Q37981765-A6151C92-3D18-4E34-A9BA-A106A2B7BDD1Q37981768-F80B961F-63FB-4084-B70B-0A87787CF351Q38082673-5EB4B5A6-65D2-48B8-B04E-48A15C22799CQ38946555-5ECDDC41-16F0-4250-B4D8-EDF44F18A362Q38992874-D9D715F6-B53A-4D59-A726-F1D0112E290BQ39041235-F3ADFAEB-0C95-495B-813F-4AD71934DD56Q39872559-5990E724-8D5A-4553-BDD9-6526C8BE13A8Q40160418-14C1199B-62FA-4DDD-8A39-1E874E1317BAQ44078558-FFF2567A-CDC7-4A03-83BE-234783D262C0Q44532649-986CBD54-F7AE-4C02-ABFD-0E2607CC1F0BQ47707295-99712CD6-A4A6-4742-B903-29790C5AC69A
P2860
The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@ast
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@en
type
label
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@ast
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@en
prefLabel
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@ast
The 23-valent pneumococcal pol ...... a comparison of meta-analyses.
@en
P1476
The 23-valent pneumococcal pol ...... a comparison of meta-analyses
@en
P304
P356
10.1023/B:EJEP.0000024701.94769.98
P577
2004-01-01T00:00:00Z
P6179
1011617306